Incredible ancient lost city from 3,500-years-ago home to the Americas' oldest civilization uncovered in Peru
The ancient city of Peñico is thought to have been a vital link between early Pacific coast settlements and remote communities deep in the Andes and Amazon.
4
4
4
Located in the northern Barranca province - around 120 miles north of Lima - the site lies around 1,970 feet above sea level.
It is believed to date back to between 1,800 and 1,500 BC - around the period that early civilisations were flourishing in the Middle East and Asia.
Archaeologists say the discovery sheds light on what became of the Americas' oldest civilisation, the Caral.
Incredible drone footage shows a circular structure on a hillside terrace at the city's centre - surrounded by the remains of stone and mud buildings.
After eight years of research 18 structures were found including ceremonial temples and residential complexes.
Objects were also discovered in buildings at the site including ceremonial objects, clay sculptures of human and animal figures and necklaces made from beads and seashells.
Peñico is located close to where Caral was established 5,000 years ago in the Supe valley of Peru, around 3,000 BC.
Recognised as the oldest known civilisation in the Americas, Caral features 32 monuments.
This includes large pyramid structures, sophisticated irrigation agriculture and urban settlements.
It is believed to have developed in isolation to other comparative early civilisations in India, Egypt, Sumeria and China.
Ancient Pompeii home unseen for 2,000 YEARS finally unearthed
Dr Ruth Shady, the archaeologist who led the recent research into Peñico and the excavation of Caral in the 1990s, said the discovery is crucial in knowing what happened after the Caral civilisation was decimated by climate change.
She told the Reuters news agency that the Peñico community was "situated in a strategic location for trade, for exchange with societies from the coast, the highlands and the jungle."
Archaeologist Marco Machacuay, a researcher with the Ministry of Culture, unveiled the findings at news conference on Thursday.
He said that Peñico's importance lies in it being a continuation of the Caral society.
Many of the Americas' most significant archaeological discoveries have been found in Peru.
This includes the Inca citadel of Machu Picchu in the Andes and the mysterious Nazca lines etched into the desert in southern Peru.
4
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
3 hours ago
- Medical News Today
Parkinson's: Cough medicine may help slow down cognitive decline
Parkinson's disease dementia develops in people who have a Parkinson's disease diagnosis. Experts are interested in finding the best ways to address and prevent Parkinson's disease dementia. A randomized clinical trial found that the drug Ambroxol may help stabilize the neuropsychiatric symptoms of Parkinson's disease dementia, and confirmed the safety of the drug's use among participants. Dementia is a common problem that remains a critical focus of clinical research. One subtype of dementia is Parkinson's disease dementia, which has to do with the mental changes that occur in some people who already have Parkinson's disease. A study published in JAMA Neurology compared the outcome of the expectorant Ambroxol with a placebo among participants with Parkinson's disease primary and secondary outcomes were similar, participants on the placebo experienced worsening neuropsychiatric symptoms compared to symptoms remaining the same in the intervention results also showed a possible improvement in cognitive symptoms for people with variants of a particular gene. Ambroxol for brain health: Potential and limitationsThe authors of the current study note the need for disease-modifying interventions for Parkinson's disease dementia. They note that focusing on a particular enzyme, beta-glucocerebrosidase, has potential, with an increase in this enzyme possibly making things better. They also note that the medication Ambroxol affects this enzyme. This study involved examining the safety of Ambroxol, how well participants tolerated the medication, and how it affected cognitive symptoms. There were 55 participants in total. All participants were over 50 years old and had confirmed Parkinson's disease for 1 year or more before developing dementia. All participants also had a study partner, someone who was in contact with them 'at least 4 days per week.'Participants took either Ambroxol or the placebo for 1 year. Researchers had trouble with recruitment for a low-dose Ambroxol group, so this group was not included in the statistical analyses of primary and secondary outcomes. Overall, there were 22 participants in the high-dose Ambroxol group and 24 participants in the placebo group. As a primary outcome, researchers evaluated participants' conditions using two evaluations: the Clinician's Global Impression of Change and the Alzheimer Disease Assessment Scale-cognitive subscale version 13. They also used other evaluation tools for secondary outcomes, including the Parkinson's Disease Cognitive Rating Scale, the Clinical Dementia Rating Scale, and the neuropsychiatric inventory. Researchers were able to look at cerebral spinal fluid and plasma biomarkers in some participants as well. Throughout the study, some participants withdrew due to adverse events. Eight participants in the Ambroxol group withdrew, and three in the placebo group in the Ambroxol group saw more gastrointestinal adverse events. The placebo group experienced more psychiatric adverse events and falls than the intervention group. In the statistical analyses, the primary and secondary outcomes between the two groups were about the same. Thus, Ambroxol did not appear to have a significant impact on cognition. However, researchers did observe that the neuropsychiatric inventory stayed the same for the Ambroxol group, but the placebo group got worse in this area, indicating the placebo group experienced worsening behavioral functioning. People at high risk of Parkinson's dementia may benefit moreThe authors of the study note that GBA1 gene variants can increase the risk for cognitive decline in people who have Parkinson's disease, and that 'homozygous disease-causing variants in GBA1' can increase the risk for Parkinson's disease. In participants with GBA1 gene variants, those taking the high-dose Ambroxol had decreases in neuropsychiatric inventory scores, three to a level of 'clinically meaningful improvement,' and three also had clinically important improved cognitive also observed increased beta-glucocerebrosidase levels among Ambroxol participants at the 26-week mark. Study author Stephen H. Pasternak, MD, PhD, FRCPC, a specialist in neurology, explained the following about the study to Medical News Today: 'Our goal was to test the safety and tolerability of Ambroxol and to assess its effect on cognition. We randomized 55 patients to Ambroxol 1,050 mg/day [milligrams per day] or placebo for 1 year. Ambroxol was well tolerated; we only saw stomach upset as a side effect, and it was mostly mild. Patients on Ambroxol had fewer psychiatric symptoms. Patients on placebo had a worsening of plasma GFAP, a marker of neurodegeneration. A subgroup of patients (with GBA1 mutations) appeared to have improved cognition.'How might a cough medication help maintain cognitive function?Pasternak told MNT that: 'We hope that Ambroxol, or drugs like Ambroxol, will be able to prevent the onset of Parkinson's disease and dementia if it is given early enough.' While more research is needed, this study sets up the possibility of using Ambroxol in the future to help people with Parkinson's disease dementia. Daniel Truong, MD, a neurologist, medical director of the Truong Neuroscience Institute at MemorialCare Orange Coast Medical Center in Fountain Valley, CA, and editor-in-chief of the Journal of Clinical Parkinsonism and Related Disorders, who was not involved in this research, explained that with future research this could lead to 'a new class of disease-modifying therapy for [Parkinson's disease dementia].Hypothesising on the potential mechanisms of action, Truong explained that:'Ambroxol, by enhancing lysosomal function via GCase [beta-glucocerebrosidase], may slow underlying neurodegeneration, especially in GBA1-related PDD [Parkinson's disease dementia] — marking a shift toward targeted disease modification rather than purely symptomatic treatment.' He also noted that this could lead to 'repurposing an established drug' as 'Ambroxol is already widely used as a mucolytic agent with a known safety profile.''This reduces development time, regulatory barriers, and cost, making it more feasible for rapid clinical adoption — especially in resource-limited settings,' Truong while it is commonly used in medical settings in many European countries, the expectorant drug is currently not approved in the United States by the Food and Drug Administration (FDA).Still, should the current study findings be confirmed by further research, Pasternak hopes experts may see the drug in a new light.'Current therapies for Parkinson's disease and dementia address symptoms but do not stop the underlying disease. These [new] findings suggest Ambroxol may protect brain function, especially in those genetically at risk. It offers a promising new treatment avenue where few currently exist,' he noted in a press research needed to confirm findingsThe study does have a few limitations. It was a fairly small study with mostly white male participants that only went on for one year. It is possible that 1 year was not long enough to evaluate changes in cognitive symptoms since the placebo group did not see declines in cognitive also note that the study was limited since it was a phase 2 trial out of a single center. They also acknowledge difficulties in recruitment and retention, and note that participants had 'limited ability to tolerate the long cognitive assessments.' The researchers did not get to conduct statistical analyses to look at differences between high and low doses of Ambroxol. They also note that the low-dose group appeared to have worse cognition. They suggest that future studies should possibly stratify participants by cognitive severity. They also acknowledge that it is possible that the Alzheimer Disease Assessment Scale-cognitive subscale version 13 might not have been sensitive enough to detect changes in 1 year in participants who had mild Parkinson's disease dementia. All participants in this study only had mild to moderate dementia. Finally, only eight participants total had GBA1 gene variants, so more research is needed to see if people in this group could experience distinct benefits from Ambroxol. Only three participants with GBA1 gene variants had the minimal clinically important difference in cognitive scores, and researchers acknowledge that 'this sample is too small to support any conclusion.' Pasternak and his colleagues are planning to conduct a follow-up clinical trial later in 2025. The current research received funding from the Garfield Weston Foundation, a grant-giving nongovernmental organisation in the United Kingdom.
BBC News
6 hours ago
- BBC News
Inside the prehistoric 'fat factory'
New research shows Neanderthals may have been even more food savvy than we first thought. Archaeologists have already found out that they would break open animal bones to get out the fatty marrow which is packed full of calories. Now new research from MONREPOS in Germany and Leiden University in the Netherlands found Neanderthals not only broke open bones, but also constructed a prehistoric 'fat factory'. Researchers used to think this sort of behaviour started later in human ancestors, but the new findings suggest it could've been part of Neanderthal behaviour too. The evidence of the 'fat factory' was found at a site in Germany called Neumark-Nord which dates back to around 125,000 years ago when the temperatures were similar to what we experience today. It was here where researchers found evidence that large mammal bones had been crushed and heated in water to made a rich bone grease. Prof. Wil Roebroeks who worked on the study said: "What makes Neumark-Nord so exceptional is the preservation of an entire landscape, not just a single site." That gives archaeologists an even better insight into how Neanderthals used to live all those years ago. "We see Neanderthals hunting and minimally butchering deer in one area, processing elephants intensively in another, and—as this study shows—rendering fat from hundreds of mammal skeletons in a centralized location. "There's even some evidence of plant use, which is rarely preserved. This broad range of behaviours in the same landscape gives us a much richer picture of their culture," he added. Although you might hear people saying to avoid fat in our modern day diets, it's a nutritionally important food group. It's full of calories which give people energy and it helps absorption of important vitamins. In a time where food might be hard to come by, filling up on fat was especially important as a source of energy. Dr. Lutz Kindler, another researcher on the project said this new study shows Neanderthals "understood both the nutritional value of fat and how to access it efficiently."
Daily Mail
11 hours ago
- Daily Mail
Nessie hunters are telling the truth! Bombshell study says those who spot the monster really are seeing something in the loch
Nessie spotters are telling the truth and really do see something in the loch, a jaw-dropping new study has revealed. But those who describe a monster with a long body forming hoops above the water may be telling porkies, the paper suggests. Experts made their findings while examining whether Nessie sightings were influenced by popular depictions of the mythical monster. What they discovered was that the stereotypical Nessie – with her body looping above the loch – is only described in a small number of sightings. And that suggests that most witnesses are being truthful, according to Charles Paxton, a statistician at the University of St Andrews, and co-author of the study. Dr Paxton said: 'The wider conclusion is that it would be wrong for people to assume that people are just making up their experiences 'I'm sure there are liars and exaggerators and things like that, but I also think that most people are reporting their own experiences. 'That doesn't mean there actually is a Loch Ness Monster, but I think witnesses, broadly speaking, are telling the truth as they've experienced it.' The loch, in the Scottish Highlands, has become synonymous with the legendary creature. The modern fascination with Nessie began in April 1933, when Aldie Mackay reported seeing a whale-like creature in the loch To see how Nessie is portrayed in popular culture, the team examined postcards depicting the mythical monster. They found that roughly 30 per cent of the sample group depicted the creature with its body looping in and out of the water. Yet only 1.5 per cent of sightings described Nessie this way. Dr Paxton said: 'There is a mismatch there. 'And that kind of implies to me that the witnesses aren't necessarily being influenced by this imagery that they see in every souvenir shop around the loch.' Those few sightings which do describe a 'hooped' Nessie are false, the researchers believe. For one thing, such a creature is 'biologically impossible', Dr Paxton said. 'It's a really inefficient way to move through water,' he explained. Some people, such as Alan McKenna, founder of Loch Ness Exploration (LNE), believes elusive 'standing waves' might explain sightings of the mythical monster Nessie sightings might just be 'standing waves' Some experts say 'standing waves' might explain sightings of the mythical monster. Alan McKenna, founder of Loch Ness Exploration, said: 'A standing wave occurs when two boat wakes of the exact same frequency and amplitude are moving in opposite directions on the loch surface. When the two boat wakes finally meet and interfere with one another the results have the potential to create a standing wave.' The peaks of standing waves, rising above the calm waters, could be mistaken for 'humps' above the surface. 'And so if people report that, they're at best mistaken or they're telling untruths.' Dr Paxton's co-author, the naturalist Adrian Shine, added: 'Basically serpents undulate laterally – horizontally – as they move through the water. 'And of course they can derive some traction from that, but not if these loops are coming out of the water. 'As a means of progression in water, it's impossible. There's nothing to push against.' Mr Shine, a fellow of the Royal Geographical Society and founder of the Loch Ness Project, says he is a 'sympathetic sceptic' when it comes to the monster. But he says the study lends credibility to those who claim to have seen Nessie. He said: 'Since they are not reporting the loops, which are the stereotypical depiction, their testimony is more likely to be true, sincere and well-observed than not.' He added: 'Our findings lend credibility to the witnesses. The burden of the paper is that the witnesses are not being influenced by the popular stereotype.' The mythical creature has captured the attention of people around the world for decades (artist's impression) Yet he remains doubtful that any mythical monster is behind the sightings. The true cause could be a mixture of boat wakes and birds, among other things. Dr Paxton was more circumspect on the Nessie debate. 'I think the Loch Ness Monster exists as a reported phenomenon,' he said. The new study was published in the journal Endeavour. What IS the Loch Ness Monster? Rumours of a strange creature living in the waters of Loch Ness have abounded over the decades, yet scant evidence has been found to back up these claims. One of the first sightings, believed to have fuelled modern Nessie fever, came in May 2, 1933. On this date the Inverness Courier carried a story about a local couple who claim to have seen 'an enormous animal rolling and plunging on the surface'. Another famous claimed sighting is a photograph taken in 1934 by Colonel Robert Kenneth Wilson. It was later exposed as a hoax by one of the participants, Chris Spurling, who, on his deathbed, revealed that the pictures were staged. Other sightings James Gray's picture from 2001 when he and friend Peter Levings were out fishing on the Loch, while namesake Hugh Gray's blurred photo of what appears to be a large sea creature was published in the Daily Express in 1933. The first reported sighting of the monster is said to have been made in AD565 by the Irish missionary St Columba when he came across a giant beast in the River Ness. But no one has ever come up with a satisfactory explanation for the sightings - although in 2019, 'Nessie expert' Steve Feltham, who has spent 24 years watching the Loch, said he thought it was actually a giant Wels Catfish, native to waters near the Baltic and Caspian seas in Europe. An online register lists more than 1,000 total Nessie sightings, created by Mr Campbell, the man behind the Official Loch Ness Monster Fan Club and is available at So what could explain these mysterious sightings? Many Nessie witnesses have mentioned large, crocodile-like scutes sitting atop the spine of the creature, leading some to believe an escaped amphibian may be to blame. Native fish sturgeons can also weigh several hundred pounds and have ridged backs, which make them look almost reptilian. Some believe Nessie is a long-necked plesiosaur - like an elasmosaur - that survived somehow when all the other dinosaurs were wiped out. Others say the sightings are down to Scottish pines dying and flopping into the loch, before quickly becoming water-logged and sinking. While submerged, botanical chemicals start trapping tiny bubbles of air.
